Skip to content

Specialty Clinical Playbook

Mohs Dermatology Scribe: Surgery and AK Destruction

Stage logs, block counts, and dated 5-FU failures, charted lesion by lesion. Book your audit at https://cal.com/merryai/demo.

Key Takeaways
  • Maps each lesion by site, size, and pathology, with dated 5-FU and imiquimod failures carried into the assessment
  • Populates the Mohs stage log with stage numbers, block counts, and margin status for 17311 through 17315
  • Keeps AK destruction counts and separately identifiable E/M problems distinct to support modifier 25
  • Chrome Extension injects structured sections directly into EHR fields without API setup

Specialty Architecture

Clinical intelligence shaped around Mohs Dermatology

Engineered to mirror the pacing, diagnostic frameworks, and documentation requirements of Mohs Dermatology.

Instant Pathology Retrieval

CONTEXT RETRIEVAL

Instant Pathology Retrieval

Recall biopsy accessions, histologic subtypes, and prior stage logs between stages without tab bouncing.

Multi-Track Diarization

SPEAKER ROUTING

Multi-Track Diarization

Separate surgeon, patient, histotechnician, and family voices, routing margin findings to the stage log and history to the E/M block.

Point-of-Care Flow

Three quiet steps from exam room to chart
your practice

Zero IT friction, zero complex API setup, and human-verified attestation on every note.

Our Chrome Extension runs directly inside the clinician's active EHR browser window with zero API fees.

Mohs Dermatology ambient recording view

Why Mohs Documentation Breaks Generic Scribes

Mohs micrographic surgery is documented at three levels at once: the lesion, the stage, and the tissue block. CMS coverage guidance and the Noridian LCD L35702 expect each lesion's anatomic location, size, number of stages, and blocks per stage, along with confirmation that the same physician served as both surgeon and pathologist. When any one of those dimensions is ambiguous, CPT 17311 through 17315 become difficult to defend, and the Recovery Audit topic on incorrect Mohs units shows reviewers are looking closely.

Generalist ambient scribes tend to produce a single narrative block. That serves a routine office visit, but a Mohs day rarely looks like one. A morning list may include a recurrent infiltrative basal cell carcinoma of the nasal ala, a well-differentiated squamous cell carcinoma on the dorsal hand, and a field of actinic keratoses on the scalp that has already failed a course of 5-fluorouracil. Each belongs in a different section of the chart, under a different code family.

Lesion-Level Mapping and Therapy Failure Chronology

Merry listens for the details a Mohs surgeon already says aloud: the site, the clinical size in millimeters, the biopsy accession and its pathology, and whether the tumor is primary or recurrent. Each lesion is held as a discrete record in transient memory, then rendered into the lesion grid rather than buried in prose.

Capturing Prior 5-FU and Imiquimod Failures

Prior topical therapy failures carry real weight in medical necessity. When a patient reports finishing a four-week course of 5-FU in March with persistent hyperkeratotic papules at follow-up, Merry records the agent, start and stop dates, duration, and the reason for failure, whether non-response or intolerance. Those dates move into the assessment so the decision for destruction or Mohs reads as a reasoned escalation rather than an isolated choice.

Risk Tiering That Supports Mohs

Appropriate use criteria hinge on location zone, size, histologic subtype, and patient factors. Merry captures H-zone placement such as the central face, periorbital skin, or ear; aggressive features such as morpheaform, infiltrative, or micronodular growth and perineural invasion; and systemic modifiers like organ transplant immunosuppression or anticoagulation. Each axis is tied back to the specific lesion it concerns.

The Mohs Stage Log and Destruction Coding

The stage log is where audit exposure concentrates. For each lesion, Merry populates stage number, blocks examined, margin status, and the histologic description when tumor is seen, including depth, growth pattern, and presence of scar. Additional stages map to 17312 or 17314, and blocks beyond five in any stage map to 17315. AK destruction is counted separately: 17000 for the first lesion, 17003 for lesions two through fourteen, or 17004 alone when fifteen or more are treated. Code descriptors should always be confirmed against the AMA CPT reference.

The matrix below summarizes how each diagnostic signal travels from the procedure room into the record.

Specialty Diagnostic MetricRequired Clinical Data PointsBilling Evidence
Lesion site and risk zoneAnatomic location, H/M/L zone, laterality17311 vs 17313 selection
Lesion size and subtypeClinical size in mm, biopsy pathology, primary vs recurrentAppropriate use and medical necessity
Stage progressionStage number, margin status per stageUnits for 17312 or 17314
Tissue block countBlocks per stage, histology when tumor present17315 for blocks beyond five
AK destruction burdenLesion count, sites, cryotherapy method17000, 17003, or 17004
Topical therapy failureAgent, start and stop dates, reason for failureEscalation rationale in assessment
Separate E/M problemsUnrelated dermatoses, medication review, counselingModifier 25 support

Separating E/M From the Procedure

A same-day E/M service must be significant and separately identifiable from the pre-operative evaluation already bundled into Mohs. Merry keeps operative detail in the procedure composer and places only distinct problems, such as rosacea management or assessment of a new pigmented lesion, into the E/M block. Distinct sites receive clear narration to support modifier 59 or the XS subset when coding staff choose them.

Chrome DOM Injection, G2211, and PHI Handling

The Chrome Extension works inside the browser window you already chart in. It identifies the visit note, the Mohs procedure grid, and pathology fields by their labels and attributes, including content rendered in iframes, and writes each section to its proper place. There is no API contract to negotiate and no interface fee.

G2211 deserves conservative handling here. CMS edits generally deny the longitudinal complexity add-on when the base E/M carries modifier 25, with exceptions limited to same-day preventive services, annual wellness visits, and vaccine administration. Merry still records longitudinal complexity, such as multiple prior skin cancers or chronic immunosuppression, but it will not suggest G2211 beside a Mohs claim. It flags the code for standalone surveillance visits where the relationship is ongoing.

Protected health information stays transient. Encounter data lives in memory only while the note is composed and injected, then is cleared. Nothing is written to local storage, and telemetry is limited to non-identifying counts. Every AI-drafted section is attributed and awaits your attestation before signing.

Specialty prompt packs for Mohs stage logs, AK destruction notes, and post-operative wound-care instructions are available at https://templates.scribing.io. They are a quiet place to start before your next surgical day.

Explore More Knowledge

Related Specialty & Practice Solutions Guides

View all specialty & practice solutions
Interventional Cardiology Notes That Win G2211
Specialty Clinical Playbook

Interventional Cardiology Notes That Win G2211

Discrete LVEF, stent date, and DAPT capture, with G2211 gated on modifier 25. Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide
Mohs Dermatology Notes That Protect Modifier 25
Specialty Clinical Playbook

Mohs Dermatology Notes That Protect Modifier 25

Separate Mohs stage maps from distinct E/M problems so modifier 25 holds under review. Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide
Interventional Cardiology Notes That Win G2211
Specialty Clinical Playbook

Interventional Cardiology Notes That Win G2211

Discrete LVEF, stent date, and DAPT capture, with G2211 gated on modifier 25. Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide